Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Targeted optical imaging of the glucagon-like peptide 1 receptor using exendin-4-IRDye800CW.

Boss M, Bos D, Frielink C, Sandker G, Ekim S, Marciniak C, Pattou F, van Dam GM, van Lith S, Brom M, Gotthardt M, Buitinga M.

J Nucl Med. 2020 Jan 10. pii: jnumed.119.234542. doi: 10.2967/jnumed.119.234542. [Epub ahead of print]

PMID:
31924726
2.

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.

Lütje S, Heskamp S, Franssen GM, Frielink C, Kip A, Hekman M, Fracasso G, Colombatti M, Herrmann K, Boerman OC, Gotthardt M, Rijpkema M.

Theranostics. 2019 May 4;9(10):2924-2938. doi: 10.7150/thno.35274. eCollection 2019.

3.

Validation of 111In-Exendin SPECT for the Determination of the β-Cell Mass in BioBreeding Diabetes-Prone Rats.

Brom M, Joosten L, Frielink C, Peeters H, Bos D, van Zanten M, Boerman O, Gotthardt M.

Diabetes. 2018 Oct;67(10):2012-2018. doi: 10.2337/db17-1312. Epub 2018 Jul 25.

4.

Non-invasive in vivo determination of viable islet graft volume by 111In-exendin-3.

Eter WA, Van der Kroon I, Andralojc K, Buitinga M, Willekens SMA, Frielink C, Bos D, Joosten L, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2017 Aug 3;7(1):7232. doi: 10.1038/s41598-017-07815-3.

5.

Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin.

van der Kroon I, Woliner-van der Weg W, Brom M, Joosten L, Frielink C, Konijnenberg MW, Visser EP, Gotthardt M.

Sci Rep. 2017 Jan 9;7:39800. doi: 10.1038/srep39800.

6.

Quantitative and longitudinal imaging of intramuscular transplanted islets of Langerhans with SPECT using [ 123 I]IBZM.

Willekens SM, van der Kroon I, Bos D, Joosten L, Frielink C, Boerman OC, Brom M, Gotthardt M.

Diabetes Obes Metab. 2017 Apr;19(4):604-608. doi: 10.1111/dom.12857. Epub 2017 Jan 30.

PMID:
27987245
7.

SPECT-OPT multimodal imaging enables accurate evaluation of radiotracers for β-cell mass assessments.

Eter WA, Parween S, Joosten L, Frielink C, Eriksson M, Brom M, Ahlgren U, Gotthardt M.

Sci Rep. 2016 Apr 15;6:24576. doi: 10.1038/srep24576.

8.

SPECT of Transplanted Islets of Langerhans by Dopamine 2 Receptor Targeting in a Rat Model.

Willekens SM, van der Kroon I, Joosten L, Frielink C, Boerman OC, van den Broek SA, Brom M, Gotthardt M.

Mol Pharm. 2016 Jan 4;13(1):85-91. doi: 10.1021/acs.molpharmaceut.5b00518. Epub 2015 Dec 4.

PMID:
26607139
9.

Graft revascularization is essential for non-invasive monitoring of transplanted islets with radiolabeled exendin.

Eter WA, Bos D, Frielink C, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2015 Oct 22;5:15521. doi: 10.1038/srep15521.

10.

(111)In-exendin uptake in the pancreas correlates with the β-cell mass and not with the α-cell mass.

Brom M, Joosten L, Frielink C, Boerman O, Gotthardt M.

Diabetes. 2015 Apr;64(4):1324-8. doi: 10.2337/db14-1212. Epub 2014 Nov 19.

11.

Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.

Lütje S, Rijpkema M, Goldenberg DM, van Rij CM, Sharkey RM, McBride WJ, Franssen GM, Frielink C, Helfrich W, Oyen WJ, Boerman OC.

Cancer Res. 2014 Nov 1;74(21):6216-23. doi: 10.1158/0008-5472.CAN-14-0594. Epub 2014 Sep 24.

12.

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.

van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lütje S, McBride WJ, Oyen WJ, Boerman OC.

Cancer Biother Radiopharm. 2014 Oct;29(8):323-9. doi: 10.1089/cbr.2014.1660. Epub 2014 Sep 16.

13.

Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Franssen GM, Lütje S, McBride WJ, Oyen WJ, Boerman OC.

Mol Imaging Biol. 2015 Feb;17(1):94-101. doi: 10.1007/s11307-014-0772-x.

PMID:
25060065
14.

Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.

Brom M, Woliner-van der Weg W, Joosten L, Frielink C, Bouckenooghe T, Rijken P, Andralojc K, Göke BJ, de Jong M, Eizirik DL, Béhé M, Lahoutte T, Oyen WJ, Tack CJ, Janssen M, Boerman OC, Gotthardt M.

Diabetologia. 2014 May;57(5):950-9. doi: 10.1007/s00125-014-3166-3. Epub 2014 Feb 1.

PMID:
24488022
15.

Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.

Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, Boerman OC.

J Nucl Med. 2014 Feb;55(2):281-6. doi: 10.2967/jnumed.113.129668. Epub 2014 Jan 9.

16.

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.

van Rij CM, Lütje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, McBride WJ, Rossi EA, Oyen WJ, Boerman OC.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1377-83. doi: 10.1007/s00259-013-2434-7. Epub 2013 May 15.

PMID:
23674207
17.

A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.

Sharkey RM, van Rij CM, Karacay H, Rossi EA, Frielink C, Regino C, Cardillo TM, McBride WJ, Chang CH, Boerman OC, Goldenberg DM.

J Nucl Med. 2012 Oct;53(10):1625-32. doi: 10.2967/jnumed.112.104364. Epub 2012 Sep 5.

18.

Surface modifications by gas plasma control osteogenic differentiation of MC3T3-E1 cells.

Barradas AM, Lachmann K, Hlawacek G, Frielink C, Truckenmoller R, Boerman OC, van Gastel R, Garritsen H, Thomas M, Moroni L, van Blitterswijk C, de Boer J.

Acta Biomater. 2012 Aug;8(8):2969-77. doi: 10.1016/j.actbio.2012.04.021. Epub 2012 Apr 20.

PMID:
22522130
19.

Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue.

Wever KE, Wagener FA, Frielink C, Boerman OC, Scheffer GJ, Allison A, Masereeuw R, Rongen GA.

PLoS One. 2011;6(8):e24276. doi: 10.1371/journal.pone.0024276. Epub 2011 Aug 30.

20.

Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.

van Rij CM, Sharkey RM, Goldenberg DM, Frielink C, Molkenboer JD, Franssen GM, van Weerden WM, Oyen WJ, Boerman OC.

J Nucl Med. 2011 Oct;52(10):1601-7. doi: 10.2967/jnumed.110.086520. Epub 2011 Aug 24.

21.

[(18)F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma.

Laverman P, Blokx WA, Te Morsche RH, Frielink C, Boerman OC, Oyen WJ, Drenth JP.

Hepatol Res. 2007 Feb;37(2):127-32.

PMID:
17300708
22.

Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.

Dijkgraaf I, Kruijtzer JA, Frielink C, Soede AC, Hilbers HW, Oyen WJ, Corstens FH, Liskamp RM, Boerman OC.

Nucl Med Biol. 2006 Nov;33(8):953-61.

PMID:
17127167
23.

Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.

Dijkgraaf I, Kruijtzer JA, Frielink C, Corstens FH, Oyen WJ, Liskamp RM, Boerman OC.

Int J Cancer. 2007 Feb 1;120(3):605-10.

24.

Biological correlates of FDG uptake in non-small cell lung cancer.

de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC, Oyen WJ.

Lung Cancer. 2007 Jan;55(1):79-87. Epub 2006 Oct 13.

PMID:
17046099
25.

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.

den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, Boerman OC, Figdor CG, Ruers TJ, Adema GJ.

Br J Cancer. 2006 Oct 9;95(7):896-905. Epub 2006 Sep 5.

26.

Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.

van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7130s-7136s.

27.

99mTc-labeled interleukin-8 for scintigraphic detection of pulmonary infections.

Rennen HJ, Bleeker-Rovers CP, van Eerd JE, Frielink C, Oyen WJ, Corstens FH, Boerman OC.

Chest. 2004 Dec;126(6):1954-61.

PMID:
15596698
28.

Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation.

Janssen M, Frielink C, Dijkgraaf I, Oyen W, Edwards DS, Liu S, Rajopadhye M, Massuger L, Corstens F, Boerman O.

Cancer Biother Radiopharm. 2004 Aug;19(4):399-404.

PMID:
15453954
29.
30.

Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2004 Feb;45(2):327-37.

31.

Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.

Brouwers AH, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.

Cancer Biother Radiopharm. 2003 Aug;18(4):539-47.

PMID:
14503948
32.

Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.

Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC.

Cancer Biother Radiopharm. 2003 Aug;18(4):525-33.

PMID:
14503946
33.

Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting.

Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, Radjopadhye M, Corstens FH, Boerman OC.

Cancer Biother Radiopharm. 2002 Dec;17(6):641-6.

PMID:
12537667
34.

Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.

Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC.

Cancer Res. 2002 Nov 1;62(21):6146-51.

35.

Modeling solid-to-solid biocatalysis: integration of six consecutive steps.

Michielsen MJ, Frielink C, Wijffels RH, Tramper J, Beeftink HH.

Biotechnol Bioeng. 2000 Sep 20;69(6):597-606.

PMID:
10918134
36.

Growth of Ca-D-malate crystals in a bioreactor.

Michielsen MJ, Frielink C, Wijffels RH, Tramper J, Beeftink HH.

Biotechnol Bioeng. 2000 Sep 5;69(5):548-58.

PMID:
10898864
37.

D-malate production by permeabilized Pseudomonas pseudoalcaligenes; optimization of conversion and biocatalyst productivity.

Michielsen MJ, Frielink C, Wijffels RH, Tramper J, Beeftink HH.

J Biotechnol. 2000 Apr 14;79(1):13-26.

PMID:
10817338

Supplemental Content

Loading ...
Support Center